(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of -4.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Tscan Therapeutics's revenue in 2024 is $21,049,000.On average, 3 Wall Street analysts forecast TCRX's revenue for 2024 to be $764,391,377, with the lowest TCRX revenue forecast at $478,821,960, and the highest TCRX revenue forecast at $1,031,861,324. On average, 3 Wall Street analysts forecast TCRX's revenue for 2025 to be $784,310,370, with the lowest TCRX revenue forecast at $478,821,960, and the highest TCRX revenue forecast at $1,052,450,668.
In 2026, TCRX is forecast to generate $909,761,724 in revenue, with the lowest revenue forecast at $153,701,849 and the highest revenue forecast at $1,665,821,599.